Amatoxin-Linker Conjugates With 6-OH Trp for Solid Tumors

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing antibody drug conjugates (ATACs) face challenges in effectively treating solid tumors, which are more resistant than liquid tumors, necessitating improved treatment options and efficacy.

Innovation Solution

Development of targeted amatoxin conjugates with specific amatoxin-linker constructs, including a 6-OH Trp residue at position 4 of the indole ring, linked to antibodies or antibody fragments via cleavable or self-immolative linkers, to enhance potency against solid tumors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional ATACs are used to treat solid tumors, then the treatment approach is simple and well-established, but the efficacy is insufficient due to resistance of solid tumors

Engineering Contradiction:

Improveefficacy against solid tumorsVSAvoidresistance of solid tumors

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent modifies the chemical structure of the amatoxin molecule by introducing a 6-OH Trp residue at position 4 of the indole ring, changing the pharmacological parameters of the toxin to achieve superior potency against solid tumors compared to conventional ATACs

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite structure by conjugating the modified amatoxin-linker construct to a target-binding moiety (antibody), combining the enhanced cytotoxicity of the modified toxin with the target-specific delivery capability of the antibody to overcome solid tumor resistance

Inventive Principle:

Principle #40Composite materials

2Reliability

If the amatoxin structure is modified to include 6-OH Trp residue, then potency against solid tumors increases, but the complexity of the molecule increases

Engineering Contradiction:

Improvepotency against solid tumorsVSAvoidmolecular structure complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent introduces a specific functional group (6-OH Trp residue) at a localized position (position 4 of the indole ring) rather than modifying the entire molecule, achieving enhanced potency with minimal structural changes

Inventive Principle:

Principle #3Local quality

3Reliability

If a cleavable linker is used to conjugate amatoxin to antibody, then the toxin can be released inside tumor cells, but the stability of the conjugate in circulation may be reduced

Engineering Contradiction:

Improvecytotoxicity release efficiencyVSAvoidconjugate stability

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent uses a cleavable linker as an intermediary component between the amatoxin and antibody, designed to be stable in circulation but cleavable inside tumor cells, thus mediating both stability and release requirements

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20260097093A1Targeted amatoxin conjugate for the treatment of solid tumors

Publication Date: 2026.04.09 HEIDELBERG PHARMA RES GMBH

AI summary

An amatoxin-linker construct contains an amatoxin according to formula (I)wherein R1 and R2 are each —OH, R3 is NH2, or a linker which carries a reactive group Y for linking said amatoxin to a target-binding moiety, R4 is H or a linker which carries a reactive group Y for linking said amatoxin to a target-binding moiety, R5 is absent or ═O, and wherein R3 and R4 cannot be the same. The amatoxin-linker construct is used in the manufacture of a binding moiety-toxin conjugate for the treatment of a solid tumor, and a respective binding moiety-toxin conjugate can be used for the treatment of a solid tumor.